About
CDI Laboratories is the NextGen Proteomics™ company, a result of intensive efforts and advances made by synthetic biologists at the Johns Hopkins University School of Medicine.
The company was created by scientists for scientists to address critical needs required accelerate research, advance discoveries, and translate these discoveries into novel products and services that improve human health. Our flagship product, HuProt™ — the Human Proteome Microarray — has gone through several upgrades in content & print quality.
Learn about the history of CDI on our News page and in the company timeline below:
Global Analysis of Protein Activities Using Proteome Chips. Heng Zhu, et al. Science (2001) DOI: 10.1126/science.1062191
Company founded as a collaboration with Johns Hopkins University and a $477K seed grant from the Puerto Rico Science, Technology, and Research Trust.
Profiling the Human Protein-DNA Interactome Reveals ERK2 as a Transcriptional Repressor of Interferon Signaling. Shaohui Hu, et al. Cell (2009) DOI: 10.1016/j.cell.2009.08.037
SBIR Phase 1 Grant: Development of an Attenuated Babesia Vaccine for Cattle.
STTR Phase I grant awarded to produce and commercialize monoclonal antibodies used to study brain-expressed proteins that are implicated in human mental disorders. The antibodies were validated using CDI’s proprietary antigen microarrays.
Application of a synthetic human proteome to autoantigen discovery through PhIP-Seq. H. Benjamin Larman, et al. Nature Biotechnology (2011) DOI: 10.1038/nbt.1856
Co-founders awarded $13.8M grant from NIH Protein Capture Reagents Program to further develop company technology in collaboration with Johns Hopkins University: Production of Affinity Reagents for Human Transcription Factors (U54) RFA-RM-10-017
VirD: A Virion Display Array for Profiling Functional Membrane Proteins. S. Hu, et al. Anal. Chem. (2013) DOI: 10.1021/ac401795y
CEO Ignacio Pino & VP Scott Paschke represents company as a ‘Presidential Ambassador for Global Entrepreneurship’ following invitation by the Obama White House.
Comprehensive serological profiling of human populations using a synthetic human virome. Stephen Elledge, et al. Science (2015) DOI: 10.1126/science.aaa0698
The NIH Protein Capture Reagents Program (PCRP): a standardized protein affinity reagent toolbox. S. Blackshaw, et al. Nature Methods. (2016). DOI: 10.1038/nmeth.4013
STTR Phase 1 Grant: Validation of immune-based biomarkers for endometriosis.
STTR Phase 1 Grant: Monospecific monoclonal antibodies against human protein complexes on an interactome- wide scale.
Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors. Gowen, et al. J Transl Med (2018) DOI: 10.1186/s12967-018-1452-4
Development and application of a high-content virion display human GPCR array. Heng Zhu, et al. Nature Communications (2019) DOI: 10.1038/s41467-019-09938-9
Immune profiling of patient antibodies using the most comprehensive antigen-specific biomarker assays ever developed. Services to industry and academia.
Highly-validated monoclonal antibodies for pathology, research, and more were developed with support from the NIH Capture Reagents Program grant. Antibodies are proven monospecific against >21,000 human proteins.
First commercial application of phage display immunoprecipitation sequencing technologies.
Release of SARS-COV-2 HuProt™ and funding from Puerto Rico Science Trust to develop tests for the virus that causes COVID-19.
Global Analysis of Protein Activities Using Proteome Chips. Heng Zhu, et al. Science (2001) DOI: 10.1126/science.1062191
Company founded as a collaboration with Johns Hopkins University and a $477K seed grant from the Puerto Rico Science, Technology, and Research Trust.
Profiling the Human Protein-DNA Interactome Reveals ERK2 as a Transcriptional Repressor of Interferon Signaling. Shaohui Hu, et al. Cell (2009) DOI: 10.1016/j.cell.2009.08.037
SBIR Phase 1 Grant: Development of an Attenuated Babesia Vaccine for Cattle.
STTR Phase I grant awarded to produce and commercialize monoclonal antibodies used to study brain-expressed proteins that are implicated in human mental disorders. The antibodies were validated using CDI’s proprietary antigen microarrays.
Application of a synthetic human proteome to autoantigen discovery through PhIP-Seq. H. Benjamin Larman, et al. Nature Biotechnology (2011) DOI: 10.1038/nbt.1856
Co-founders awarded $13.8M grant from NIH Protein Capture Reagents Program to further develop company technology in collaboration with Johns Hopkins University: Production of Affinity Reagents for Human Transcription Factors (U54) RFA-RM-10-017
Rapid identification of monospecific monoclonal antibodies using a human proteome microarray. J Jeong, et al. Molecular & Cellular Proteomics (2012) DOI: 10.1074/mcp.O111.016253
VirD: A Virion Display Array for Profiling Functional Membrane Proteins. S. Hu, et al. Anal. Chem. (2013) DOI: 10.1021/ac401795y
CEO Ignacio Pino & VP Scott Paschke represents company as a ‘Presidential Ambassador for Global Entrepreneurship’ following invitation by the Obama White House.
Comprehensive serological profiling of human populations using a synthetic human virome. Stephen Elledge, et al. Science (2015) DOI: 10.1126/science.aaa0698
The NIH Protein Capture Reagents Program (PCRP): a standardized protein affinity reagent toolbox. S. Blackshaw, et al. Nature Methods. (2016). DOI: 10.1038/nmeth.4013
STTR Phase 1 Grant: Validation of immune-based biomarkers for endometriosis.
STTR Phase 1 Grant: Monospecific monoclonal antibodies against human protein complexes on an interactome- wide scale.
Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors. Gowen, et al. J Transl Med (2018) DOI: 10.1186/s12967-018-1452-4
Development and application of a high-content virion display human GPCR array. Heng Zhu, et al. Nature Communications (2019) DOI: 10.1038/s41467-019-09938-9
Immune profiling of patient antibodies using the most comprehensive antigen-specific biomarker assays ever developed. Services to industry and academia.
Highly-validated monoclonal antibodies for pathology, research, and more were developed with support from the NIH Capture Reagents Program grant. Antibodies are proven monospecific against >21,000 human proteins.
First commercial application of phage display immunoprecipitation sequencing technologies.
Release of SARS-COV-2 HuProt™ and funding from Puerto Rico Science Trust to develop tests for the virus that causes COVID-19.